Molecular Partners (MOLN) to Announce Earnings on Tuesday

Molecular Partners (NASDAQ:MOLN) is anticipated to announce its Q2 2026 results before the market opens on Tuesday, August 25th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 25, 2026 at 3:00 AM ET.

Molecular Partners Price Performance

Shares of Molecular Partners stock opened at $4.40 on Monday. Molecular Partners has a 12 month low of $3.53 and a 12 month high of $5.36. The stock has a market cap of $177.67 million, a PE ratio of -2.27 and a beta of 1.08. The business has a fifty day simple moving average of $4.02 and a 200-day simple moving average of $4.23.

Wall Street Analyst Weigh In

MOLN has been the subject of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research report on Wednesday, July 8th. HC Wainwright reissued a “buy” rating on shares of Molecular Partners in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.38.

Institutional Investors Weigh In On Molecular Partners

A hedge fund recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,311 shares of the company’s stock, valued at approximately $54,000. Institutional investors own 26.55% of the company’s stock.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.